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Abstract
Background:  The post marketing safety surveillance program for a drug containing a new
chemical entity should assess both, the safety outcomes that relate specifically to the targeted
population, as well as those that could potentially be related to special pharmacological
characteristics of the drug. Active safety surveillance using valid epidemiological study designs has
been proven to be a pertinent and reliable method to approach this endeavor.
Methods/design: The primary objective of the study is to compare incidence rates of serious
adverse events in users of all types of newly prescribed oral HRT products. This active surveillance
study will assess pertinent cardiovascular outcomes - in particular venous and arterial
thromboembolism - and other serious adverse events (SAEs) in new HRT users over a period of
several years. One product under surveillance is Angeliq®, which contains the novel progestagen
drospirenone (DRSP) combined with estradiol. In addition, all other oral combined HRT products
with a novel progestagen or estrogen that will be newly marketed during the study period will be
studied. These new HRT products will be compared with established HRT products. The combined
cohort will include at least 30,000 women recruited in several European countries. At least 90,000
years of observation are expected from the field work which started in early 2002 and will end
around 2008. The participating women will complete a baseline survey using a self-administered
questionnaire to describe the baseline risk. After 6 months, 12 months, and then on an annual basis,
they will fill out a questionnaire in which they record complaints and events during the use of the
prescribed HRTs. All adverse outcomes occurring during the observational period will be
evaluated.
Discussion: A complete lifetime medical history, individually validated SAEs over time, and a low
loss to follow-up rate are essential for a robust safety assessment. Therefore, the lifetime history
of diseases and relevant medications will be documented. Reported SAEs will be validated and
analyzed. A four level, multi-faceted follow-up process was established to ensure low loss to follow-
up rates (e.g., 3–5% after three years of follow up). Multivariate methods will be used to adjust for
confounding.
Background
The safety of a novel drug product containing a new chem-
ical entity should be assessed in an extensive post market-
ing safety surveillance program. It is also prudent to assess
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both, the safety outcomes that relate specifically to the tar-
geted population, as well as those that could potentially
be related to the special pharmacological characteristics of
the novel drug product. Differentiating between the inher-
ent background population risk and a potential incremen-
tal risk due to treatment is often challenging. Active safety
surveillance using valid epidemiological study designs has
been proven to be a pertinent and reliable method to
approach this endeavor.
Long-term active safety surveillance of new HRT products
has gained particular importance following the intense
scientific debate on the risk/benefit profile of HRT prod-
ucts after the publication of the WHI results [1]. The active
safety surveillance study proposed in this protocol, the
European Active Surveillance Study of Women taking
HRT (EURAS-HRT) study, will assess the risk profile of
marketed oral combined HRT products, by comparing
HRT products that contain novel progestagens with older
HRT products. The primary objective of the study is to
compare incidence rates of serious adverse events - in par-
ticular cardiovascular outcomes - in new users of all types
of oral HRT products. This large, multinational, prospec-
tive, controlled, non-interventional, long-term cohort
study will follow a series of cohorts for a period of seven
years. The study is sponsored by Schering AG with an
unconditional grant. Study conduct and data analysis are
carried out by an independent investigator under the
stewardship of an international advisory committee.
One drug product under surveillance in the EURAS - HRT
study is Angeliq®, which contains a novel synthetic pro-
gestagen drospirenone (DRSP) [2,3] combined with estra-
diol. In addition, all other oral combined HRT products
with a novel progestagen or estrogen that will be newly
marketed during the study period will be included in this
study. These new HRT products will be compared with
established HRT products.
As estrogen/progestagen combinations increase the risk
for thrombembolism [4], all new drug products that con-
tain a novel estrogen or progestagen should be investi-
gated for their influence on venous and arterial
thromboembolic events rates. A large, prospective, con-
trolled cohort study of OC users (EURAS OC Study),
which compared DRSP-containing OCs users with other
OCs users, demonstrated that DRSP is not associated with
an increased incidence for thromboembolic events in OC
users [5]. However, because OC users are two to three dec-
ades younger than the typical HRT user the results of the
OC study can only partially be extrapolated to older age
groups.
Furthermore, given DRSP's antimineralocorticoide phar-
macological characteristics, specific outcomes such as the
risk of hyperkalemia and dysrhythmia, and subsequent
serious cardiac problems will be assessed in this study. As
secondary objective all other outcomes of the long-term
observation will be evaluated.
A long-term observational cohort study, which compares
rates of adverse events among users of Angeliq® (and other
new HRT products) with those among users of other mar-
keted oral HRTs, is an appropriate design to assess long-
term risks and benefits under real-life-conditions of drug
utilization, i.e. taking into account all possible interac-
tions with co-morbidity and co-treatment which are com-
mon in higher age groups. Potential differences between
first-time users of an HRT product and users who switch
from one preparation to another will be investigated.
Moreover, the potential of greater risk during the early
period of use (e.g. the first year) will be carefully moni-
tored.
The pilot phase of this surveillance study was started in
early 2002, using a cohort of women who visited Euro-
pean physicians who prescribe HRT. This revised protocol
reflects the experiences gained in the pilot phase of the
study. Further background information and details are
available at the study's website [6].
Methods/design
Objectives
The study will monitor utilization practice with particular
attention to long-term effects in user cohorts of: 1)
Angeliq (and potentially of other novel oral continuous-
combined HRT products); 2) other oral continuous-com-
bined HRTs; and 3) other oral HRTs
under routine conditions, all of these in the medical prac-
tice of several European countries.
The study will compare incidence rates of serious or unex-
pected adverse events among users of the three above-
mentioned HRT user cohorts to analyze the following:
- Events that played a key role in earlier risk considerations,
such as myocardial infarction, stroke, sudden death, and
venous thromboembolism;
- Other medically significant events.
The study is not designed to investigate long-term out-
comes such as breast, colon, or endometrial cancer or
osteoporotic fractures, on account of the expected small
number of cases and relatively short treatment periods.
However, all serious or unexpected outcomes will be fully
documented, and evaluated. This means that significant
adverse events will be analyzed under "real-life condi-
tions", i.e. without influencing the prescription behaviorBMC Women's Health 2006, 6:1 http://www.biomedcentral.com/1472-6874/6/1
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of the physicians or the desires of the women. It is under-
stood that HRTs will be prescribed according to interna-
tional guidelines.
Design
Prospective, controlled cohort study of users of HRT with
follow-up: one cohort of women starting with or switch-
ing to Angeliq®, one comparison cohort of other oral con-
tinuous-combined HRT users (starter or switcher), and a
third cohort of all other marketed oral HRTs (starter or
switcher).
Study participants
The combined cohorts will include at least 30,000 women
aged 40 or more years who started or switched to an oral
HRT at the time of inclusion in the study.
Following an indication for hormone replacement ther-
apy, the prescribing physicians will determine whether
women are eligible to participate. The primary objective is
to accrue women in early or late menopause. For some
women, postmenopausal status will be unclear and they
will be described as "perimenopausal". Perimenopausal
women who are prescribed oral HRTs will be included in
this study. There will be stratified analyses for women
who were clearly menopausal and women for whom this
was not clear for various reasons (e.g., treatment). Women
newly taking a herbal menopausal remedy are not eligible
for inclusion. Different HRT formulations will be distin-
guished during the analysis.
Additional study inclusion criteria will not be given.
Rather study inclusion will be the decision of the individ-
ual prescribing physician after explaining the benefits and
risks to the woman. This approach supports the aim of the
active surveillance study, which is to reflect drug use under
real-life conditions. Evaluation of data for certain sub-
groups such as "HRT switchers" and "perimenopausal
women" can be performed later in the analysis. Subgroup
analyses for certain age groups will also be considered.
The women will be asked if they are willing to participate
after being fully informed about the study. Women who
start with hormone replacement or switch from another
HRT can be included. For each woman who receives a pre-
scription for the new HRT at a given center, one woman
who receives an HRT prescription from each of the other
two groups will be selected.
Women who do not consent to a long-term follow-up
study, who have contraindications for HRT, or who have
language difficulties, will not be eligible.
Information gathered
Exposure data
Exposure is defined - for this surveillance study - as new
use of any oral HRT. This includes women who are first
time users (starters) or those who switch to a new brand.
The exposure group of particular interest is the group
using Angeliq®, and two other exposure groups (other oral
continuous-combined HRT products and all other oral
HRT products) have been defined as comparators (see
above). Herbal menopausal drugs and SERMS will not be
included in the main analysis.
Confounding and effect-modifying factors
Factors considered as confounders, effect modifiers, or
adjustment variables will include the following: age,
smoking, hypertension, increased blood lipids, treated
diabetes mellitus, body mass index, cardiovascular dis-
eases (angina pectoris, myocardial infarction, stroke/TIA,
venous thromboembolism), and family history of prema-
ture cardiovascular events (MI and stroke). If other poten-
tial confounders are identified in the analyses they will be
adjusted for as appropriate.
Outcomes: The outcomes of particular interest are: cardio-
vascular mortality, incidence rates of myocardial infarc-
tion, stroke, and venous thromboembolism.
The relevant information will be gathered by means of a
short self-administered questionnaire to be completed by
the participating women (including consultation with
their physicians if necessary). The baseline questionnaire
will contain questions related to the state of health, risk
factors (medical history), and confounders, including
drug use. The follow-up assessment of the combined
cohort will be done after 6 months, 12 months, and then
on an annual basis by means of a questionnaire mailed to
the cohort members. This follow-up questionnaire con-
centrates on experience with the newly prescribed HRT.
The study will end when the last woman in the study com-
pletes the first year of follow-up and the average follow-up
has extended for at least three years.
The questionnaires document the following information:
• Baseline: ID number; birthday; date of last menstrual
bleeding; artificial menopause (operation); parity/births
(number); OC use, age at start and stop, duration of OC
use; any HRT use, how many different brands, duration of
HRT, how many switches among brands, date of HRT ces-
sation, name of last brand, name of current prescription;
smoking status (current, former, never), number of ciga-
rettes now and before cessation, date of cessation; medical
history of relevant diseases such as myocardial infarction,
arrhythmias (confirmed by ECG), stroke, pulmonary
embolism, deep venous thrombosis, varicose veins, frac-BMC Women's Health 2006, 6:1 http://www.biomedcentral.com/1472-6874/6/1
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tures, any cancer; family history of myocardial infarction
or stroke, VTE, breast cancer; regular use of medicaments
(specify); recent blood pressure reading, height/weight.
• Follow-up: ID number; occurrence of new conditions
after last contact such as myocardial infarction, stroke,
venous thromboembolism; fractures (specify); any cancer
(specify), any other severe health problems (specify); hos-
pitalizations (specify); all brand names of HRTs used
since last contact, including dates; regular use of medica-
ments (specify); changes in smoking status; weight/
height; other relevant information; personal changes;
name of treating physician/hospital to enable contact (if
an AE/SAE has occurred).
If the women report serious adverse events (SAEs), the
investigators will discuss these events with the women
and the treating physician(s). Serious adverse events will
be reported to the respective manufacturer regardless of
whether the attending physician already reported the
event through official channels in the respective country.
Necessary steps will be taken to facilitate rapid reporting
in the event of unexpected SAEs.
Data handling
The questionnaire will first be checked manually for com-
pleteness and consistency at the coordinating center. In
case of missing data, contradictions, questions, or obvious
errors, the participants will be contacted for clarification.
After completion of manual checks, the forms will be
entered into an electronic database designed to meet the
specific needs of a long-term cohort study.
Non-respondents will be sent a second, and if necessary, a
third mailing. The names and addresses of the remaining
non-respondents will then be checked in compliance with
national laws to obtain information about possible
changes. For any remaining non-respondents, attempts at
tracing will be made using the contact persons named at
the time of last contact.
To further maximize follow-up after the baseline survey,
the women will be asked at every contact to announce any
personal changes, e.g. telephone numbers. If a woman
reports any of a specified list of medical outcomes, a fol-
low-up form will be sent to request consent to inspect the
medical records. Information on the name of the relevant
physician, hospital, etc. will be recorded in order to gain
access to the records.
Study size estimation
The follow-up of at least 30,000 women will generate
90,000 or more women-years within the 5–6 year study
period.
The sample size calculation is based on estimates for the
incidence of important outcomes in this age group and a
market share of 10% for the new HRT product(s) of inter-
est: cardiovascular mortality (0.5%), non-fatal myocardial
infarction (0.2%), stroke (0.2%), and VTE (0.3%).
To detect an increased risk of certain outcomes associated
with new HRT products with 95% probability and a
power of 80%, the roughly required number of women-
years of the combined cohort should have the following
magnitude for a detectable rate ratio of 3.0: cardiovascular
mortality about 44,000 women-years, myocardial infarc-
tion 30,000, and venous thromboembolism 20,000.
Therefore the expected 90,000 women-years should be
sufficient to investigate the adverse events of interest.
Evaluation
Based on a priori considerations of the clinical pharmacol-
ogy of the new continuous-combined HRT Angeliq® and
also other HRTs, there is a substantial potential for con-
founding in this study. It will not be possible to confine
the study to non-predisposed women, since an important
objective in this study is to determine risk according to the
baseline risk status. It will be important to control con-
founding and to evaluate possible effect modification
from various sources. Reported serious adverse events will
be validated with medical records. Ascertainment of
deaths - in particular sudden death - will be accomplished
by cross-reference to relevant death registries (in countries
were access to these registries are permitted by national
law).
Interim evaluations
Descriptive statistics of the interim results will be pre-
sented twice a year to the Advisory Council, including
data on the number of women enrolled in the three user
cohorts, observed duration and type of HRT use, number
and nature of serious AEs for all three HRT cohorts, and as
soon as sufficient numbers are available also stratified by
starters and switchers, or - if relevant - by certain formula-
tions or specific events (e.g. sudden death, cardiovascular
events, or other major events), provided that sufficient
numbers have been obtained or the nature of the events is
serious, unexpected, or relevant for the study objectives.
Any adverse events mentioned in the follow-up question-
naires or received as separate reports will be compiled by
local investigators and forwarded to the international
coordinating center in Berlin. Additional information will
be sought as appropriate: Firstly, the reporting patient will
be contacted again to confirm the absence of misunder-
standing and to acquire more information about symp-
toms and other circumstances. These include
confirmation of name/address of the treating physician.
Depending on the results, contact will be made with rele-BMC Women's Health 2006, 6:1 http://www.biomedcentral.com/1472-6874/6/1
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vant health professionals to gain access to detailed medi-
cal information to confirm the (new) event/diagnosis.
The clinical seriousness, causality, and possible associa-
tion of each reported adverse event with HRT use will be
assessed.
For the overall safety assessment, the relevant data as well
as conclusions will be submitted to the Advisory Council
as part of the next scheduled progress report, or immedi-
ately in case of urgency. There may be a need for interim
safety reports that can be published after assessment by
the AC.
Final analysis
The primary aim of the analysis is to assess cardiovascular
effects; the secondary objective is to evaluate all other out-
comes of the long-term observation. A detailed analysis
plan was prepared and reviewed/approved by the Advi-
sory Committee in September 2004 and March 2005.
Several issues have to be considered in the analysis and
interpretation. For example, it cannot be excluded that
women who were prescribed the most recently launched
HRT (here Angeliq®) will be found systematically to be at
higher risk than women who were prescribed older HRTs.
In addition, it cannot be excluded that starters (first ever
users) of the new continuous-combined HRT (Angeliq®)
have an even higher baseline risk than starters of other
recent HRTs due to the physicians' prescription behavior,
which is influenced by the expectation of a safer "new
HRT". Furthermore, women who have previously used
older HRTs may be at lower risk than new users, because,
on average, these will have used the older HRTs for a
longer period of time whereas those who experienced car-
diovascular events will no longer be using them. Compar-
isons between first-time users of HRTs should therefore be
easier to interpret.
To adjust for confounding and effect modification, multi-
variate methods will be used. It is anticipated that there
may be complex sources of bias and confounding, e.g.
many risk factors could contribute to the relevant out-
comes. In interpreting the findings, therefore, the greatest
emphasis will be on relative risk estimates of high magni-
tude. Low relative risk estimates (under 2.0 - 3.0) will be
considered inconclusive, because it is methodologically
impossible to distinguish between causation, bias, and
confounding. Any apparently increased relative risk, if
present, will be evaluated based on the magnitude of the
observed hazard ratio. In interpreting the impact of results
on public health (safety), the main emphasis will be on
absolute risk estimates.
The focus will be on prudent analysis with appropriate
statistical adjustment procedures across centers and coun-
tries. Comparisons among countries are not the aim of the
study but could be made on request of the Advisory Coun-
cil.
The final analysis will be based on life-table methods
comparing the three main cohorts of users. All analyses
will make allowance for confounding, using methods that
will include multivariate techniques such as Cox regres-
sion, stratification by the Mantel-Haenszel procedure, and
exclusion of women with specific confounders at baseline.
Some confounders that can be precisely quantified (e.g.
smoking status, obesity) will not be excluded but rather
controlled for in the analysis.
Ethics and privacy
The planning and performance of the study are subject to
national laws. The study was only started after meeting all
requirements of the appropriate regulatory authorities. It
will be conducted in accordance with the ethical princi-
ples of the Declaration of Helsinki. The study was
approved by the ethical committee in Duivendrecht, The
Netherlands (Medisch Ethische Toetsingscommissie of
the Stichting Therapeutische Evaluatie Geneesmiddelen)
in May 2004. The study is registered in the public clinical
trials registry of the US National Library of Medicine
under the registration number NCT00214903.
The women participate on a voluntary basis. The women
will be asked if they are willing to participate, i.e. to report
complaints/symptoms/events for years under the assump-
tion that their data will be kept anonymous and will be
evaluated/reported as statistics only. The nature of the
study will be explained to each woman prior to her entry
into the study, including its purpose and associated proce-
dures as well as the expected duration of the study, i.e.
including potential benefits and side effects of HRT. After
consenting, the women will receive signed and dated
duplicates of the volunteer information and informed
consent forms. Each woman will have ample opportunity
to ask questions and will be informed about the right to
withdraw from the study at any time without any disad-
vantage and without having to provide reasons for this
decision.
Women and treating physicians will be kept anonymous
in the scientific database. Names and addresses will be
stored under lock and separately from the scientific (ques-
tionnaire) data. Protocol and study material were submit-
ted to the relevant Data Privacy Institution. The
specifications of the respective data protection laws will
be followed.
Advisory council
An independent Advisory Council (AC) consisting of epi-
demiologists, gynecologists, cardiologists, and otherBMC Women's Health 2006, 6:1 http://www.biomedcentral.com/1472-6874/6/1
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experts of international reputation is responsible for over-
seeing the study. The AC met for the first time on 18 Feb-
ruary 2004. Names and terms of reference are given in the
annex. The AC will continue to meet several times during
the study period. Non-voting representatives of the spon-
sor and the investigator will attend the meetings. At the
end of each meeting the AC evaluates the findings in exec-
utive sessions without the investigator and the sponsor.
Study management
The Centre for Epidemiology & Health Research Berlin, an
independent scientific institution experienced in interna-
tional, multicentric observational studies, is responsible
for planning and conducting the study in Europe. It will
coordinate the fieldwork in different countries and sub-
contract with local investigators to handle language barri-
ers.
Discussion
Estrogen/Progestagen combinations increase the risk of
venous thromboembolism, as a class. As illustrated by the
WHI study on HRT these products increase venous throm-
boembolism maximally during the first year of use, after
which the risk declines (starter effect) [1]. Women who
are susceptible to VTE probably experience a thrombosis
soon after they start HRT intake and then stop treatment.
Therefore, a population of long-term users who do not
switch between different preparations includes only a few
high-risk patients and therefore has a low VTE rate. The
starter effect repeats itself at a lower level after a period of
discontinuation (re-starter effect) [7,8]. Furthermore,
women at high risk tend selectively to switch to the most
recently marketed product (switcher effect). For the sake
of the validity of the study results and the comparability
of the cohorts it is essential to record precise information
on duration of use, discontinuation periods and risk fac-
tors. Long-term users of a HRT preparation should not be
included in the study.
The diagnosis of venous and arterial thromboembolism is
not always confirmed by methods with a high sensitivity
and specificity (e.g., phlebography). Therefore, the classi-
fication of reported thromboembolic events has to be
done by a predefined algorithm. Definite and probable
events will be considered as confirmed. All other cases will
be classified as "not confirmed".
One of the most crucial factors to ensure the validity of the
study is a low "lost to follow-up" rate. In order to mini-
mize loss to follow-up a multi-faceted, four level follow-
up process was established. The level1 activities include
the mailing of the follow-up questionnaire and - in case a
woman does not respond - two reminder letters. If level1
activities do not lead to a response multiple attempts are
made to contact her, her husband, friends, relatives and
the gynecologist/primary care physician per phone. In
parallel to these level2 activities searches in national and
international telephone and address directories are started
(level3 activities). If this is not successful, an official
address search via the respective governmental adminis-
tration is conducted (in some countries centralized, in
others decentralized at community level). This level4
activity can provide information on a new address (or
information that the respondent has moved abroad or has
died). If necessary, a search in the national death registers
could be started at the end of the study to clarify the vital
status of patients who are lost to follow-up after level4
activities. Overall, the investigators estimate that the loss
to follow-up of the combined cohort could be kept at less
than 5% of the recruited population.
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